RecruitingNot ApplicableNCT06440759

To Compare the Efficacy and Safety of Using oXiris and M100 During CRRT

Evaluation of Efficacy and Safety Using oXiris Versus M100 Filter in Pneumonia-induced Acute Kidney Injury (AKI) Patients Requiring Continuous Renal Replacement Therapy (CRRT)

Sponsor

Mohd Zulfakar Mazlan, MBBS

Enrollment

60 participants

Start Date

May 30, 2024

Study Type

INTERVENTIONAL

Conditions

Pneumonia AKI - Acute Kidney Injury

Summary

The purpose of this study aimed to compare the efficacy of Oxiris (Baxter) and M100 filters on IL-6 as primary outcomes and other blood cell counts, blood biochemistry (serum urea, creatinine, potassium, sodium), inflammation indicators (CRP, PCT), as secondary outcomes and safety (28 days mortality as a primary outcome and coagulopathy, lifespan of filter, usage of vasopressor, clinical conditions (ventilator-free days, ICU and hospital- length of stay) as a secondary outcome), clinical conditions (ventilator-free days, ICU and hospital- length of stay), and mortality of patients with pneumonia-related AKI.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

All adult patients aged\>18 years old
Diagnosis of septic shock
Diagnosis of KDIGO stage 3 acute renal failure

Exclusion Criteria3

Moribund patient or patient that is expected to die within 72 hours
Pregnancy
patient with a bleeding tendency or known allergy to heparin

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEoXiris filter

Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris. The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.

DEVICEM100 filter

Continuous Renal Replacement Therapy with the adsorption membrane filter M100. The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.